« Previous
Next »
Cardiovascular Revascularization Medicine
Volume 10, Issue 1
, Pages 17-22
, January 2009
Metal allergic reaction in chronic refractory in-stent restenosis
References
- Randomized study with the sirolimus-coated BX Velocity balloon-expandable stent in the treatment of patients with de nove native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–1780
- SIRIUS sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323
- . Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries; double blind, randomized controled trial (E-SIRIUS). Lancet. 2003;362:1093–1099
- The Canadian study of the sirolimus-eluting stent in the treatment of patients with ling de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004;43:1110–1115
- A polymer-based, paclitaxel eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221–231
- Paclitaxel coating reduces in-stent intimal hyperplesia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation. 2003;107:517–520
- Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol. 2005;45:954–959
- . Contact allergies to metal components of the 316L steel in patients with coronary heart disease: Mat.-wiss. U. Werkstofftech. 2002;33:747–750
- . Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet. 2000;356:1895–1897
- . Is there a link between nickel allergy and coronary stent restenosis?. Tohoku J Exp Med. 2005;206(3):243–246
- . The impact of metallic allergy on stent implantation: metal allergy and recurrence of in-stent restenosis. Int J Cardiol. 2005;104(3):319–325
- Summary of safety and effectiveness data. Cypher™ Sirolimus-eluting OTW and RX CSS PMA#P020026.
- Summary of safety and effectiveness data. TAXUS™ Express2™ Coronary Stent System. PMA#P030025.
- Outcome of target sites escaping high-grade (>70%) restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1999;83:857–861
- . Morphological predictors of restenosis after coronary stenting in humans. Circulation. 2002;105:2974–2980
- . Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation. 2003;108:1701–1706
- Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron Artery Dis. 2002;13:183–188
- . Pathology of drug-eluting stents in humans. Delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193–202
- Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation. 2005;112:270–278
- . Silicon carbide as an anti-thrombogenic stent coating: an example of science-based development strategy. Prog Biomed Res. 2000;5:168–178
- . Smart material silicon carbide: reduced activation of cells and proteisns on a-SiC: H-coated syainless steel. Prog Biomed Res. 2001;182–194
- Measurement of cytokine secretion, intracellular protein expression, and mRNA in resting and stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol. 2000;7(6):920–924
- . Nickel, cobalt, chromium, palladium and gold induce a mixed Th1- and Th2-cytokine response in vitro in subjects with contact allergy the respective metals. Clin Exp Immunol. 2006;146:417–726
PII: S1553-8389(08)00005-5
doi: 10.1016/j.carrev.2008.01.004
© 2009 Elsevier Inc. All rights reserved.
« Previous
Next »
Cardiovascular Revascularization Medicine
Volume 10, Issue 1
, Pages 17-22
, January 2009
